NCT01505491 - Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects | Biotech Hunter

Enrollment

193

Participants

Timeline

Start Date

December 1, 2011

Primary Completion Date

July 1, 2012

Study Completion Date

July 1, 2012

Conditions

Healthy

Interventions

DRUG

adalimumab

40mg adalimumab single s.c. injection

DRUG

BI695501

BI 695501 single s.c injection

DRUG

adalimumab

40mg adalimumab single s.c. injection

Trial Locations (2)

1297.1.002 Boehringer Ingelheim Investigational Site, Auckland

1297.1.001 Boehringer Ingelheim Investigational Site, Christchurch